Experimental Design, a Key Component in Drug Development
Monday 2 June, 1:20--2:20

Organizer: Frank SHEN
Bristol-Myers Squibb
Moderator: Frank SHEN
Bristol-Myers Squibb

Experimental Design, a Key Component in Drug Development

Randolph L. GREASHAM
Merck and Co., Inc., Rahway, NJ, USA
A large number of important pharmaceutical drugs is produced either fully (such as MEVACOR) or partially (as key chemical intermediates; ZOCOR) by microorganisms. These compounds as well as the microorganisms that produce them are usually identified through extensive screening programs. Once a product candidate is identified, a process to produce this compound in large quantities must be rapidly developed to support chemical modification and safety assessment studies. The number of environmental parameters important to microbial growth and product synthesis is quite great, including both chemical (such as nutrient requirements) and physical (such as temperature and pH) factors. Therefore, the employment of a full factorial search is often too time consuming, requiring for example a total of 729 separate experimental trials to evaluate six nutrients at three concentrations. To achieve enhanced productivities in a timely manner, a combination of partial factorial searches (such as Plackett-Burman and Box-Behnken designs) and pattern searches (such as the sequential simplex method) are frequently employed.

[Randolph L. GREASHAM, Merck and Co., Inc., Rahway, NJ, randolph\_greasham@merck.com]


Back to JRC program
Back to JRC Home Page